Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · Aug 28, 2017

Keywords

ClinConnect Summary

This clinical trial is studying whether a special type of MRI called dynamic contrast-enhanced MRI (DCE-MRI) can help doctors predict how well children with retinoblastoma will respond to a treatment called intra-arterial chemotherapy. Retinoblastoma is a type of eye cancer that mostly affects young children, and while most children respond well to current treatments, some may not. By using DCE-MRI, the researchers hope to identify early signs of how effective the chemotherapy will be for each child.

To participate in this trial, children must have retinoblastoma classified as grade B to D and be prescribed intra-arterial chemotherapy. There are no specific exclusions based on other health conditions. If eligible, participants will receive the usual treatment and undergo MRI scans to help gather important information about their response to the therapy. This research could lead to better treatment plans and outcomes for children with retinoblastoma in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • grade B to D retinoblastoma
• • prescription of intra arterial chemotherapy
• Exclusion Criteria:
• • none